Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SUPN vs VNDA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SUPN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

SUPN Overall Winner 6-Pillar Tally: SUPN 6 – 0 VNDA Matrix Metrics: SUPN 8 – 2 VNDA

As of Nov 16, 2026, Supernus Pharmaceuticals, Inc. (SUPN) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SUPN carries a Unified Composite Score of 51.3/100 (HOLD) at $28.90 (7.4x Forward P/E, 46.9% operating margin), whereas VNDA carries 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin).

  • Technical & Structure Timing Caution: SUPN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.9); meanwhile VNDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SUPN vs VNDA
SUPN NASDAQ Head-to-Head Winner
Supernus Pharmaceuticals, Inc.
Pharmaceutical Preparations
$28.90
-2.76% 1D
Market Cap $6.1B
TTM Revenue $1.37B
Forward P/E 7.4x
Beta / 30D Vol 0.76β · 125% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 58.0 Fund 63.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.4%), weak momentum, RSI 31
RSI-14: 30.9 · SMA20: $34.72 · SMA50: $39.26
VNDA NASDAQ
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations
$3.79
-4.89% 1D
Market Cap $238.9M
TTM Revenue $229M
Forward P/E 103.1x
Beta / 30D Vol 1.25β · 61% Vol
Unified Composite Score
49.0 / 100 HOLD
Tech 56.0 Fund 58.0 Flow 65.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.9%), weak momentum, RSI 40
RSI-14: 40.0 · SMA20: $3.95 · SMA50: $4.46

6-Pillar Scorecard Institutional Category Breakdown (SUPN 6 – 0 VNDA)

Columns: Metric · SUPN · VNDA
1. Valuation Multiples SUPN
Forward P/E 7.4x 103.1x
Trailing P/E 20.2x 103.1x
PEG Ratio 1.47x 2.23x
EV / Revenue 4.3x 0.9x
2. Growth & Scale SUPN
Revenue Growth (YoY) +13.4% +24.1%
Earnings Growth (YoY) +239.4% -95.9%
TTM Revenue (USD) $1.37B $229M
Market Cap $6.1B $238.9M
3. Profitability & Quality SUPN
Gross Margin 85.7% 93.6%
Operating Margin 46.9% -77.6%
Net Profit Margin 32.8% -119.9%
Return on Equity (ROE) -4.2% -82.5%
4. Balance Sheet & Cash Flow SUPN
Cash Generation (TTM) $87M -$150M
Cash Flow Margin 6.3% -65.4%
Net Cash / Leverage $140M Net Cash $40M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SUPN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 81.3% (20th %ile) 163.3% (75th %ile)
Put/Call OI Skew 0.59x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat SUPN
OpEx & R&D Intensity 38.8% of Rev ($533M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SUPN (8) vs VNDA (2)
Institutional Metric SUPN VNDA Criterion Row Edge
Market Capitalization
Scale
$6.1B $238.9M Larger Scale SUPN
Trailing P/E Ratio
Valuation
20.2x 103.1x Lower Multiple SUPN
Forward P/E Ratio
Valuation
7.4x 103.1x Lower Multiple SUPN
Revenue Growth (YoY)
Growth
+13.4% +24.1% Higher Growth VNDA
Operating Margin (TTM)
Profitability
46.9% -77.6% Higher Margin SUPN
Net Profit Margin
Profitability
32.8% -119.9% Higher Margin SUPN
Return on Equity (ROE)
Capital Efficiency
-4.2% -82.5% Higher ROE SUPN
52-Week Range Position
Momentum
9% ($26–$60) 4% ($4–$10) Stronger Trend SUPN
Beta / 30D Volatility
Risk Regime
0.76β · 125% Vol 1.25β · 61% Vol Lower Realized Risk VNDA
Unified Institutional Score
Composite Signal
51.3 / 100 (HOLD) 49.0 / 100 (HOLD) Higher Composite SUPN
Trailing 12M Revenue (USD)
Operating Scale
$1.37B $229M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
85.7% 93.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.47x PEG · 4.3x EV/Rev 2.23x PEG · 0.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$87M ($140M Net Cash) -$150M ($40M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VNDA +16.46 pp
SUPN: -26.96% · VNDA: -10.5%
3M Horizon VNDA +12.28 pp
SUPN: -40.13% · VNDA: -27.85%
6M Horizon VNDA +1.96 pp
SUPN: -41.53% · VNDA: -39.57%
1Y Horizon VNDA +22.41 pp
SUPN: -34.97% · VNDA: -12.56%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SUPN Revenue VNDA Revenue SUPN Op. Margin VNDA Op. Margin Margin Leader
FY2018 $410M $190M 35.3% 11.3% SUPN
FY2019 $390M $230M 37.8% 10.0% SUPN
FY2020 $520M $250M 33.4% 11.0% SUPN
FY2021 $580M $270M 14.8% 15.7% VNDA
FY2022 $670M $250M 6.9% 2.5% SUPN
FY2023 $610M $190M -0.9% -7.2% SUPN
FY2024 $660M $200M 12.3% -20.5% SUPN
FY2025 $720M $220M -8.7% -70.0% SUPN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SUPN BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 81.3%
IV Percentile 20th %ile
Put/Call OI Skew 0.59x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SUPN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VNDA BREAKDOWN
174d in phase · OBV NEUTRAL
Current IV 163.3%
IV Percentile 75th %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VNDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SUPN Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $6.1B market capitalization and 46.9% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($533M)
90D Engineering Disclosures 0 Published
VNDA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.9M market capitalization and -77.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SUPN vs VNDA Key Questions & Quantitative Answers

As of Nov 16, 2026, Supernus Pharmaceuticals, Inc. (SUPN) is the stronger overall head-to-head candidate over Vanda Pharmaceuticals Inc. (VNDA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SUPN carries a Unified Composite Score of 51.3/100 (HOLD) at $28.90 (7.4x Forward P/E, 46.9% operating margin), whereas VNDA carries 49.0/100 (HOLD) at $3.79 (103.1x Forward P/E, -77.6% operating margin). Technical & Structure Timing Caution: SUPN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.9); meanwhile VNDA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SUPN leads the Growth & Scale pillar: SUPN posts +13.4% YoY revenue growth and +239.4% YoY earnings growth on $1.37B TTM revenue (85.7% gross margin, 46.9% operating margin), compared with VNDA at +24.1% YoY revenue growth and -95.9% YoY earnings growth on $229M TTM revenue (93.6% gross margin, -77.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), SUPN cumulative revenue shifted +75.6% while VNDA shifted +15.8%. In operating R&D and SG&A reinvestment, SUPN deploys 38.8% of Rev ($533M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VNDA.

SUPN screens cheaper on headline valuation multiples. SUPN trades at 7.4x Forward P/E, 20.2x Trailing P/E, 1.47x PEG, and 4.3x EV/Revenue (6.3% FCF margin), whereas VNDA trades at 103.1x Forward P/E, 103.1x Trailing P/E, 2.23x PEG, and 0.9x EV/Revenue (-65.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SUPN (-4.2% ROE) versus VNDA (-82.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SUPN carries 81.3% implied volatility (20th %ile, Compressed (<25th %ile)), a 0.59x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.76β · 125% Vol realized risk). By comparison, VNDA carries 163.3% implied volatility (75th %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.25β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.